University of Saskatchewan

Merial Sas

Ciba-geigy Canada Ltd.

The University of British Columbia

Other

Merial Limited

Qatar University

Dalhousie University

Veterinary Infectious Disease Organization

International Vaccines Institute

University of Saskacthewan

Kenya Agriculture and Livestock Research Organization (kalro)

International Liverstock Research Institute (ilri)

The Queen's University of Belfast

International Vaccine Institute

Andrew A Potter

Philip J Willson

Lorne A Babiuk

Jose Perez-Casal

Michael Fontaine

Li Wang

Amalia Rossi-Campos

Huw P Hughes

Gerald F Gerlach

Catherine Elisabeth Charreyre

John R Harding

Brian Martin Meehan

John Ellis

Gilles Emile Chappuis

Gordon Moore Allan

Edward Clark

Lori Hassard

Francis McNeilly

Deborah Haines

John G Manns

Alexandra J Bolton

Mark J Redmond

Manuel Campos

Neil R Cashman

Anthony Bernard Schryvers

Scott Napper

Volker Gerdts

Richard J Harland

Clement R Rioux

Avijit Chakrabartty

Robert E Hancock

B Brett Finlay

Jennifer Kovacs-Nolan

Philip Griebel

Scott Halperin

Peter Hedlin

Melissa Elliott

Jason Kindrachuk

Mi-Na Kweon

Philip Ronald MacLachlan

Min Jiang

Song Lee

Xinming Song

George Mutwiri

Sylvia Van Den Hurk

Reggie Y C Lo

Sylvia Van Drunen Littel-van Den Hurk

Haitham Tawfiq Ghunaim

Dragan Rogan

Marawan A Abu Madi

Brenda J Allan

Hezron Wesonga

Jan Naessens

Joerg Jores

Reuben Soi

Yejun Wang

Patrick John Frenchick

David Asper

Huw P A Hughes

Xin Ming Song

Ryan Taschuk

Kristen Marciniuk

Brenda Allan

Michael Theisen

James Elton Gilchrist

Mohammad Khalid Ijaz

Marta Iris Sabara

Brett Finlay

Phillip Willson

Philipp Willson

Immunogenic proteins comprisingsubsp.andsubsp.proteins, encoding polynucleotides, a method for producing said proteins, and use of compositions to preventsubsp.infections are disclosed.

vaccines and uses thereof

Provided herein are compositions and methods for vaccinating against infection with pathogenic(). In some embodiments, the compositions may include a vaccine including an immunogenic portion of at least twoproteins described herein.

[object Object]

Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.

Prion disease-specific epitopes and methods of use thereof

Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen.

Combination adjuvant formulation

Prion epitopes and methods of use thereof

Compositions and methods for stimulating an immune response against Shiga toxin-producing(STEC) antigens are disclosed. The compositions include a multiple epitope fusion protein comprising more than one epitope of an immunogenic STEC protein from more than one STEC serotype. Additional compositions include at least two purified STEC proteins, wherein the STEC proteins are selected from a full-length STEC protein, an immunogenic fragment or variant thereof, wherein at least one of the STEC proteins generates antibodies that react with STEC O157 and at least one other STEC serotype.

Compositions and methods for stimulating an immune response against a secreted enterohemorragic(EHEC) antigen are disclosed. The compositions comprise EHEC cell culture supernatants.

The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.

Postweaning multisystemic wasting syndrome and porcine circovirus from pigs

The GapC plasmin binding protein genes of(),(),(),(), and() are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.

Postweaning multisystemic wasting syndrome virus from pigs

The CAMP factor gene of() is described, as well as the recombinant production of CAMP factor therefrom. Also disclosed are chimeric CAMP factor constructs, including CAMP factor epitopes from more than one bacterial species. The CAMP factors and chimeras including the same can be used in immunogenic compositions for the prevention and treatment of bacterial infections.

Growing community of inventors

Saskatoon, Canada

Andrew A Potter